{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T00:17:55Z","timestamp":1792282675113,"version":"4.4.0"},"reference-count":21,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,7]]},"abstract":"<jats:title>Abstract:<\/jats:title>\n          <jats:p>Vemurafenib has proved to be useful in the treatment of patients with unresectable or metastatic melanoma harboring the BRAF-V600E mutation, with better rates of overall and progression-free survival than previous treatments. Adverse cutaneous effects, such as alopecia, pruritus, photosensitivity reactions, verrucous keratosis, keratoacanthomas, or squamous cell carcinomas, have been described. Thirty cases of vemurafenib-associated panniculitis are available in the literature with variable clinical relevance. Only 9 of them exhibited definitive evidence of neutrophilic panniculitis. They all consist of multiple lesions, usually located in the lower limbs. Histopathologically, they have been described as predominantly neutrophilic, lymphocytic, or mixed, more commonly with lobular location. We report an additional case of neutrophilic panniculitis in a 45-year-old woman treated with vemurafenib for metastatic melanoma, presenting as a single lesion on his right leg. The lesion resolved spontaneously and did not need treatment reduction. The presentation of this condition with a single lesion is particularly challenging. Recognition of this association is important given the increasing use of vemurafenib and the potential implications of treatment withdrawal.<\/jats:p>","DOI":"10.1097\/dad.0000000000000528","type":"journal-article","created":{"date-parts":[[2016,3,9]],"date-time":"2016-03-09T06:18:40Z","timestamp":1457504320000},"page":"e93-e96","source":"Crossref","is-referenced-by-count":24,"title":["Vemurafenib-Induced Neutrophilic Panniculitis: A New Case and Review of the Literature"],"prefix":"10.1097","volume":"38","author":[{"given":"Igor","family":"V\u00e1zquez-Osorio","sequence":"first","affiliation":[{"name":"Dermatology, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Dolores","family":"S\u00e1nchez-Aguilar","sequence":"additional","affiliation":[{"name":"Dermatology, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Garc\u00eda-Rodi\u00f1o","sequence":"additional","affiliation":[{"name":"Dermatology, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 M.","family":"Su\u00e1rez-Pe\u00f1aranda","sequence":"additional","affiliation":[{"name":"Pathology, Clinical University Hospital and School of Medicine, Santiago de Compostela, Spain."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Aliste","sequence":"additional","affiliation":[{"name":"Pathology, Clinical University Hospital and School of Medicine, Santiago de Compostela, Spain."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugo","family":"V\u00e1zquez-Veiga","sequence":"additional","affiliation":[{"name":"Dermatology, and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230908","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.2165\/11640870-000000000-00000","article-title":"Vemurafenib: targeted inhibition of mutated BRAF for treatment of advanced melanoma and its potential in other malignancies","volume":"72","author":"Sharma","year":"2012","journal-title":"Drugs"},{"key":"R2-20230908","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved survival with vemurafenib in melanoma with BRAF V600E mutation","volume":"364","author":"Chapman","year":"2011","journal-title":"N Engl J Med."},{"key":"R3-20230908","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1056\/NEJMoa1112302","article-title":"Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib","volume":"366","author":"Sosman","year":"2012","journal-title":"N Eng J Med."},{"key":"R4-20230908","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1111\/bjd.12010","article-title":"Cutaneous adverse events associated with vemurafenib in patients with metastatic melanoma: practical advice on diagnosis, prevention and management of the main treatment-related skin toxicities","volume":"167","author":"Sinha","year":"2012","journal-title":"Br J Dermatol."},{"key":"R5-20230908","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1093\/annonc\/mdt015","article-title":"Prospective study of cuatenous side-effects associated with the BRAF inhibitor vemurafenib: a study of 42 patients","volume":"24","author":"Boussemart","year":"2013","journal-title":"Ann Oncol."},{"key":"R6-20230908","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1016\/j.jaad.2012.04.008","article-title":"Diverse cutaneous side effects associated with BRAF inhibitor therapy: a clinicopathologic study","volume":"67","author":"Chu","year":"2012","journal-title":"J Am Acad Dermatol."},{"key":"R7-20230908","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.5858\/arpa.2014-0270-CC","article-title":"Neutrophilic panniculitis: algorithmic approach to a heterogeneous group of disorders","volume":"138","author":"Chan","year":"2014","journal-title":"Arch Pathol Lab Med."},{"key":"R8-20230908","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.jaad.2003.10.006","article-title":"Neutrophilic panniculitis","volume":"50","author":"Sutra-Loubet","year":"2004","journal-title":"J Am Acad Dermatol."},{"key":"R9-20230908","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1001\/archdermatol.2011.2842","article-title":"Panniculitis with arthralgia in patients with melanoma treated with selective BRAF inhibitors and its management","volume":"148","author":"Zimmer","year":"2012","journal-title":"Arch Dermatol."},{"key":"R10-20230908","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1097\/CMR.0b013e3283570792","article-title":"Vemurafenib-induced neutrophilic panniculitis","volume":"22","author":"Monfort","year":"2012","journal-title":"Melanoma Res."},{"key":"R11-20230908","doi-asserted-by":"crossref","first-page":"e271","DOI":"10.1016\/j.jaad.2012.05.019","article-title":"Vasculitis and panniculitis associated with vemurafenib","volume":"67","author":"Novoa","year":"2012","journal-title":"J Am Acad Dermatol."},{"key":"R12-20230908","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1684\/ejd.2013.1991","article-title":"Vemurafenib-induced panniculitis","volume":"23","author":"Villani","year":"2013","journal-title":"Eur J Dermatol."},{"key":"R13-20230908","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1111\/cup.12149","article-title":"Neutrophilic panniculitis developing after treatment of metastatic melanoma with vemurafenib","volume":"40","author":"Kim","year":"2013","journal-title":"J Cutan Pathol."},{"key":"R14-20230908","doi-asserted-by":"crossref","first-page":"e320","DOI":"10.1200\/JCO.2012.45.8307","article-title":"Erythema nodosum-like panniculitis in patients with melanoma treated with vemurafenib","volume":"31","author":"Sinha","year":"2013","journal-title":"J Clin Oncol."},{"key":"R15-20230908","doi-asserted-by":"crossref","first-page":"16","DOI":"10.5070\/D370X41670","article-title":"Vemurafenib-associated neutrophilic panniculitis: an emergent adverse effect of variable severity","volume":"19","author":"Maldonado-Seral","year":"2013","journal-title":"Dermatol Online J."},{"key":"R16-20230908","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1684\/ejd.2012.1915","article-title":"Erythema nodosum in a patient undergoing vemurafenib therapy for metastatic melanoma","volume":"23","author":"Degen","year":"2013","journal-title":"Eur J Dermatol."},{"key":"R17-20230908","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1111\/jdv.12397","article-title":"BRAF inhibitors-induced panniculitis: a cutaneous side effect mimicking subcutaneous melanoma metastasis","volume":"29","author":"Chaminade","year":"2015","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"R18-20230908","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1111\/jdv.13039","article-title":"Eryhema nodosum-like lesions during BRAF inhibitor therapy: report on 16 new cases and review of the literature","volume":"29","author":"M\u00f6ssner","year":"2015","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"R19-20230908","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/nature00766","article-title":"Mutations of the BRAF gene in human cancer","volume":"417","author":"Davies","year":"2002","journal-title":"Nature"},{"key":"R20-20230908","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1111\/j.1365-2133.2010.10185.x","article-title":"Frequencies of BRAF and NRAS mutations are different in histological types and sites of origin of cutaneous melanoma: a meta-analysis","volume":"164","author":"Lee","year":"2011","journal-title":"Br J Dermatol."},{"key":"R21-20230908","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1097\/DAD.0000000000000023","article-title":"Panniculitis in patients treated with BRAF inhibitors: a case series","volume":"36","author":"Choy","year":"2014","journal-title":"Am J Dermatopathol."}],"container-title":["The American Journal of Dermatopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00000372-201607000-00026","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,8]],"date-time":"2023-09-08T04:02:49Z","timestamp":1694145769000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00000372-201607000-00026"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7]]},"references-count":21,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1097\/dad.0000000000000528","relation":{},"ISSN":["0193-1091"],"issn-type":[{"value":"0193-1091","type":"print"}],"subject":[],"published":{"date-parts":[[2016,7]]}}}